KZIA Wutah pendapatan triwulanan Kazia Therapeutics Limited

Simbol lan logo merek kaziatherapeutics.com (KZIA)

Kazia Therapeutics (KZIA) develops anti-tumor agents where global scaling potential is constrained by the clinical testing phase. Market capitalization is based on the future sale of drugs for complex forms of brain cancer. Optimized chemical compound supplies eliminate research disruptions. The current quarterly revenue growth rate demonstrates the business trajectory, and 164.40 expresses today's metric value, capturing the balance between stability and yield.

kaziatherapeutics.com (KZIA) - Tingkat wutah pendapatan sajrone kuartal saka 04.07.2022 nganti 21.11.2026

Kazia (KZIA) - rincian metrik lan laporan keuangan

- kuotasi saiki lan rata-rata prakiraan nilai:
Analisis umum perusahaan:kaziatherapeutics.com (KZIA)
Barang unggulan Kazia Therapeutics Ltd

For the aggressive brain tumor therapy innovator Kazia Therapeutics (KZIA), the quarterly revenue growth rate serves as an indicator of the commercialization of unique molecules capable of crossing the blood-brain barrier. This metric calculates the percentage change in current revenue relative to the previous quarter, where negative dynamics signal a contraction in operational activity and necessitate a revision of the asset retention strategy in favor of more stable instruments.

Pesaing utama

INCY - Wutah pendapatan kuartal marang kuartal|Owah-owahan pendapatan dibandhingake kuartal kepungkur HUTCHMED (HCM)|NUVB: Wutah pendapatan triwulanan|Owah-owahan pendapatan dibandhingake kuartal kepungkur Day One Bio DAWN|Wutah dodolan triwulanan MNPR|Tingkat wutah pendapatan sajrone kuartal Inhibrx Biosciences INBX|Wutah dodolan triwulanan IMAB (I-Mab Biopharma Co., Ltd.)|FENC (Fennec Pharmaceuticals Inc.) - Tambahing pendapatan triwulanan|Heron Therapeutics, Inc. - Wutah dodolan triwulanan|Owah-owahan dodolan kuartal marang kuartal NVCT (Nuvectis Pharma)|Coherus BioSciences, Inc. - Wutah pendapatan triwulanan|Tambahing pendapatan triwulanan CRBP (Corbus Pharma)|CRDF: Wutah pendapatan triwulanan|Tingkat wutah pendapatan sajrone kuartal beyondspringpharma.com (BYSI)|Wutah pendapatan kuartal marang kuartal bioatla.com|LIXT: Tambahing pendapatan triwulanan|Wutah pendapatan triwulanan CTXR|Wutah pendapatan triwulanan Cellectar Corp (CLRB)|Wutah pendapatan kuartal marang kuartal BioLineRx Corp BLRX|CANF (Can-Fite BioPharma Ltd.) - Dinamika pendapatan kuartal marang kuartal|APRE: Wutah dodolan triwulanan|Tingkat wutah pendapatan sajrone kuartal Silexion Therapeutics|NuCana plc (NCNA) - Wutah pendapatan kuartal marang kuartal|Wutah dodolan triwulanan Chimerix, Inc|Wutah dodolan triwulanan CYCC|Wutah dodolan triwulanan G1 Therapeutics (GTHX)|Wutah pendapatan kuartal marang kuartal Kronos Bio Corporation (KRON)|Kintara - Wutah dodolan kuartal marang kuartal|Oncternal Therapeutics, Inc. - Wutah dodolan triwulanan|Owah-owahan dodolan kuartal marang kuartal PRTG (Portage)